Comparison of efficacy of endogenous and exogenous IGF-I in stimulating matrix production in neonatal and mature chondrocytes

Izath N. Aguilar, Stephen Trippel, Shuiliang Shi, Lawrence J. Bonassar

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective. The goal of this study was to compare the efficacy of endogenous upregulation of IGF-I by gene therapy and exogenous addition of insulin-like growth factor I (IGF-I) in enhancing proteoglycan synthesis by skeletally mature and neonatal chondrocytes. Chondrocyte transplantation therapy is a common treatment for focal cartilage lesions, with both mature and neonatal chondrocytes used as a cell source. Additionally, gene therapy strategies to upregulate growth factors such as IGF-I have been proposed to augment chondrocyte transplantation therapies. Methods. Both skeletally mature and neonatal chondrocytes were exposed to either an adeno-associated virus-based plasmid containing the IGF-I gene or exogenous IGF-I. Results. Analysis of IGF-I and glycosaminoglycan production using a 4-parameter dose-response model established a clear connection between the amount of IGF-I produced by cells and their biosynthetic response. Both neonatal and mature chondrocytes showed this relationship, but the sensitivities were quite different, with EC50 of 0.57 ng/mL for neonatal chondrocytes and ED50 of 8.70 ng/mL IGF-I for skeletally mature chondrocytes. Conclusions. These data suggest that IGF-I gene therapy may be more effective with younger cell sources. Both cell types were less sensitive to exogenous IGF-I than endogenous IGF-I.

Original languageEnglish (US)
Pages (from-to)264-272
Number of pages9
JournalCartilage
Volume6
Issue number4
DOIs
StatePublished - Jan 1 2015

Fingerprint

Insulin
Chondrocytes
Insulin-Like Growth Factor I
Gene therapy
Genetic Therapy
Intercellular Signaling Peptides and Proteins
Up-Regulation
Transplantation
Dependovirus
Cartilage
Viruses
Proteoglycans
Glycosaminoglycans
Genes
Plasmids
Therapeutics

Keywords

  • Cartilage Development
  • Gene Therapy
  • Growth Factor
  • Osteoarthritis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Biomedical Engineering
  • Physical Therapy, Sports Therapy and Rehabilitation

Cite this

Comparison of efficacy of endogenous and exogenous IGF-I in stimulating matrix production in neonatal and mature chondrocytes. / Aguilar, Izath N.; Trippel, Stephen; Shi, Shuiliang; Bonassar, Lawrence J.

In: Cartilage, Vol. 6, No. 4, 01.01.2015, p. 264-272.

Research output: Contribution to journalArticle

Aguilar, Izath N. ; Trippel, Stephen ; Shi, Shuiliang ; Bonassar, Lawrence J. / Comparison of efficacy of endogenous and exogenous IGF-I in stimulating matrix production in neonatal and mature chondrocytes. In: Cartilage. 2015 ; Vol. 6, No. 4. pp. 264-272.
@article{e07a72c9b9df4d698e4803a8f222abb2,
title = "Comparison of efficacy of endogenous and exogenous IGF-I in stimulating matrix production in neonatal and mature chondrocytes",
abstract = "Objective. The goal of this study was to compare the efficacy of endogenous upregulation of IGF-I by gene therapy and exogenous addition of insulin-like growth factor I (IGF-I) in enhancing proteoglycan synthesis by skeletally mature and neonatal chondrocytes. Chondrocyte transplantation therapy is a common treatment for focal cartilage lesions, with both mature and neonatal chondrocytes used as a cell source. Additionally, gene therapy strategies to upregulate growth factors such as IGF-I have been proposed to augment chondrocyte transplantation therapies. Methods. Both skeletally mature and neonatal chondrocytes were exposed to either an adeno-associated virus-based plasmid containing the IGF-I gene or exogenous IGF-I. Results. Analysis of IGF-I and glycosaminoglycan production using a 4-parameter dose-response model established a clear connection between the amount of IGF-I produced by cells and their biosynthetic response. Both neonatal and mature chondrocytes showed this relationship, but the sensitivities were quite different, with EC50 of 0.57 ng/mL for neonatal chondrocytes and ED50 of 8.70 ng/mL IGF-I for skeletally mature chondrocytes. Conclusions. These data suggest that IGF-I gene therapy may be more effective with younger cell sources. Both cell types were less sensitive to exogenous IGF-I than endogenous IGF-I.",
keywords = "Cartilage Development, Gene Therapy, Growth Factor, Osteoarthritis",
author = "Aguilar, {Izath N.} and Stephen Trippel and Shuiliang Shi and Bonassar, {Lawrence J.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1177/1947603515578691",
language = "English (US)",
volume = "6",
pages = "264--272",
journal = "Cartilage",
issn = "1947-6035",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Comparison of efficacy of endogenous and exogenous IGF-I in stimulating matrix production in neonatal and mature chondrocytes

AU - Aguilar, Izath N.

AU - Trippel, Stephen

AU - Shi, Shuiliang

AU - Bonassar, Lawrence J.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objective. The goal of this study was to compare the efficacy of endogenous upregulation of IGF-I by gene therapy and exogenous addition of insulin-like growth factor I (IGF-I) in enhancing proteoglycan synthesis by skeletally mature and neonatal chondrocytes. Chondrocyte transplantation therapy is a common treatment for focal cartilage lesions, with both mature and neonatal chondrocytes used as a cell source. Additionally, gene therapy strategies to upregulate growth factors such as IGF-I have been proposed to augment chondrocyte transplantation therapies. Methods. Both skeletally mature and neonatal chondrocytes were exposed to either an adeno-associated virus-based plasmid containing the IGF-I gene or exogenous IGF-I. Results. Analysis of IGF-I and glycosaminoglycan production using a 4-parameter dose-response model established a clear connection between the amount of IGF-I produced by cells and their biosynthetic response. Both neonatal and mature chondrocytes showed this relationship, but the sensitivities were quite different, with EC50 of 0.57 ng/mL for neonatal chondrocytes and ED50 of 8.70 ng/mL IGF-I for skeletally mature chondrocytes. Conclusions. These data suggest that IGF-I gene therapy may be more effective with younger cell sources. Both cell types were less sensitive to exogenous IGF-I than endogenous IGF-I.

AB - Objective. The goal of this study was to compare the efficacy of endogenous upregulation of IGF-I by gene therapy and exogenous addition of insulin-like growth factor I (IGF-I) in enhancing proteoglycan synthesis by skeletally mature and neonatal chondrocytes. Chondrocyte transplantation therapy is a common treatment for focal cartilage lesions, with both mature and neonatal chondrocytes used as a cell source. Additionally, gene therapy strategies to upregulate growth factors such as IGF-I have been proposed to augment chondrocyte transplantation therapies. Methods. Both skeletally mature and neonatal chondrocytes were exposed to either an adeno-associated virus-based plasmid containing the IGF-I gene or exogenous IGF-I. Results. Analysis of IGF-I and glycosaminoglycan production using a 4-parameter dose-response model established a clear connection between the amount of IGF-I produced by cells and their biosynthetic response. Both neonatal and mature chondrocytes showed this relationship, but the sensitivities were quite different, with EC50 of 0.57 ng/mL for neonatal chondrocytes and ED50 of 8.70 ng/mL IGF-I for skeletally mature chondrocytes. Conclusions. These data suggest that IGF-I gene therapy may be more effective with younger cell sources. Both cell types were less sensitive to exogenous IGF-I than endogenous IGF-I.

KW - Cartilage Development

KW - Gene Therapy

KW - Growth Factor

KW - Osteoarthritis

UR - http://www.scopus.com/inward/record.url?scp=84960359242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960359242&partnerID=8YFLogxK

U2 - 10.1177/1947603515578691

DO - 10.1177/1947603515578691

M3 - Article

AN - SCOPUS:84960359242

VL - 6

SP - 264

EP - 272

JO - Cartilage

JF - Cartilage

SN - 1947-6035

IS - 4

ER -